+Compare
ALZN
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
70.77M

ALZN Price Prediction, Alzamend Neuro AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ALZN with price predictions
08:00 PM EDT Jun 01, 2023

ALZN's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ALZN turned positive on May 24, 2023. Looking at past instances where ALZN's MACD turned positive, the stock continued to rise in of 18 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 22, 2023. You may want to consider a long position or call options on ALZN as a result. In of 29 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ALZN moved above its 50-day moving average on May 22, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ALZN advanced for three days, in of 85 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALZN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALZN broke above its upper Bollinger Band on May 24, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ALZN entered a downward trend on May 25, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.077) is normal, around the industry mean (25.150). P/E Ratio (0.000) is within average values for comparable stocks, (123.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.331). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (308.288).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I. Advisor
published Earnings

ALZN is expected to report earnings to -5 cents per share on June 28

Alzamend Neuro ALZN Stock Earnings Reports
Q2'23
Est.
$-0.06
Q1'23
Missed
by $0.02
Q4'22
Beat
by $0.01
Q3'22
Beat
by $0.04
Q2'22
Missed
by $0.02
The last earnings report on March 16 showed earnings per share of -5 cents, missing the estimate of -3 cents. With 263.84K shares outstanding, the current market capitalization sits at 70.77M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.12B. The market cap for tickers in the group ranges from 365 to 350.31B. NONOF holds the highest valuation in this group at 350.31B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 31%. EFTR experienced the highest price growth at 77%, while BLCM experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3500 Lenox Road NE
Phone
+1 844 722-6333
Employees
7
Web
https://www.alzamend.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ACHHY11.450.75
+7.01%
Aluminum Corp
FRHLF10.700.37
+3.58%
Freehold Royalty Ltd
WFAFY15.880.12
+0.73%
Wesfarmers Ltd
RCGCF0.13N/A
N/A
ROSCAN GOLD Corp
LHDXQ0.06-0.02
-25.30%
Lucira Health

ALZN and

Correlation & Price change

A.I.dvisor tells us that ALZN and INMB have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALZN and INMB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALZN
1D Price
Change %
ALZN100%
-5.56%
INMB - ALZN
33%
Poorly correlated
+0.26%
RCKT - ALZN
31%
Poorly correlated
+4.35%
FIXX - ALZN
31%
Poorly correlated
-1.30%
AXON - ALZN
30%
Poorly correlated
+0.58%
MDGL - ALZN
29%
Poorly correlated
-3.38%
More